Stock listing

NASDAQ:UPB Upstream Bio, Inc. Stock

Home listing (NASDAQ) of Upstream Bio, Inc.

Follow Upstream Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:UPB

$1.59 USD -0.41 (-20.5%)

Close on Nov 20, 2026

Past year -93.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.56 – $2.06 USDNov 20, 2026
Volume
1.39M sharesNov 20, 2026
Market cap
$87.15M USDAt the close on Nov 20, 2026 · price × 54.81M shares outstanding
52-week range
$1.56 – $33.68 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.95M USDMedian day 947,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Upstream Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:UPB · Home$1.59 USD-0.41 (-20.5%)1,386,100$1.98$2.06$1.56$2.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:UPB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.59-0.41-20.5%$1.98$2.06$1.561,386,100
$2.00-0.08-3.8%$2.09$2.19$2.00856,100
$2.08-0.02-1.0%$2.16$2.19$2.051,239,200
$2.10-0.05-2.3%$2.10$2.205$2.0051,182,800
$2.15-0.63-22.7%$2.82$2.83$2.121,993,300
$2.78-0.08-2.8%$2.86$2.98$2.73891,300
$2.86-0.34-10.6%$3.13$3.13$2.802,528,600
$3.20-0.18-5.3%$3.38$3.46$3.131,318,100
$3.38-0.20-5.6%$3.52$3.655$3.241,175,000
$3.58+0.35+10.8%$3.23$3.595$3.171,983,600
$3.23+0.02+0.6%$3.24$3.28$3.021,139,900
$3.21-0.49-13.2%$3.64$3.675$3.001,064,600
$3.70+0.31+9.1%$3.59$3.843$3.521,246,900
$3.39+0.04+1.2%$3.36$3.525$3.305978,500
$3.35-0.06-1.8%$3.42$3.46$3.16936,100
$3.41+0.14+4.3%$3.26$3.425$3.15946,100
$3.27+0.29+9.7%$3.00$3.32$2.971,178,800
$2.98+0.19+6.8%$2.78$2.99$2.681,323,100
$2.79+0.04+1.5%$2.76$2.935$2.681,179,600
$2.75+0.01+0.4%$2.75$2.97$2.72983,800
$2.74-0.25-8.4%$2.95$2.96$2.6951,051,200
$2.99+0.19+6.8%$2.77$2.99$2.701,450,000
$2.80-0.02-0.7%$2.83$2.975$2.7651,410,500
$2.82+0.02+0.7%$2.79$3.09$2.781,676,000
$2.80+0.04+1.4%$2.76$3.07$2.751,603,700
$2.76-0.61-18.1%$3.39$3.39$2.741,836,400
$3.37-0.05-1.5%$3.44$3.555$3.2851,285,300
$3.42-0.13-3.7%$3.475$3.60$3.291,572,500
$3.55-0.62-14.9%$4.14$4.155$3.521,037,400
$4.17-0.53-11.3%$4.68$4.72$4.12848,400
$4.70+0.15+3.3%$4.54$4.76$4.511,187,800
$4.55-0.06-1.3%$4.53$4.65$4.3652,857,200
$4.61+0.02+0.4%$4.55$4.72$4.50908,400
$4.59-0.26-5.4%$4.84$4.865$4.531,062,300
$4.85-0.19-3.8%$5.07$5.10$4.6651,010,600
$5.040.000.0%$5.12$5.21$4.86956,500
$5.04-0.23-4.4%$5.25$5.345$4.98832,400
$5.27+0.08+1.5%$5.23$5.455$5.145851,200
$5.19-0.11-2.1%$5.28$5.305$4.99784,200
$5.30-0.06-1.1%$5.34$5.385$5.12615,400
$5.36+0.19+3.7%$5.20$5.39$5.07429,200
$5.17-0.02-0.4%$5.19$5.20$5.045566,600
$5.19-0.30-5.5%$5.48$5.49$4.985553,000
$5.49+0.125+2.3%$5.44$5.56$5.38360,400
$5.365+0.025+0.5%$5.42$5.44$5.27364,000
$5.34+0.03+0.6%$5.32$5.41$5.211,001,000
$5.31-0.02-0.4%$5.44$5.48$5.235533,900
$5.33-0.15-2.7%$5.49$5.54$5.27497,200
$5.48-0.33-5.7%$5.81$5.81$5.455421,300
$5.81+0.08+1.4%$5.75$5.87$5.70491,000
$5.73-0.02-0.3%$5.84$5.84$5.65501,300
$5.75-0.21-3.5%$5.86$5.86$5.67562,400
$5.96-0.23-3.7%$6.14$6.20$5.77726,200
$6.19+0.18+3.0%$6.01$6.21$5.77949,700
$6.01-0.07-1.2%$6.00$6.23$5.965642,900
$6.08-0.40-6.2%$6.49$6.49$5.771,351,800
$6.48-0.07-1.1%$6.62$6.98$6.41515,400
$6.55-0.07-1.1%$6.58$6.72$6.50476,500
$6.62-0.07-1.0%$6.64$6.77$6.44895,000
$6.69-0.10-1.5%$6.71$6.79$6.60445,500
$6.79-0.34-4.8%$7.11$7.14$6.78335,100
$7.13-0.05-0.7%$7.18$7.31$6.90432,900
$7.18+0.57+8.6%$6.68$7.18$6.55554,420
$6.61-0.36-5.2%$7.00$7.11$6.46538,545
$6.97+0.12+1.8%$6.91$7.006$6.85434,200
$6.85-0.665-8.8%$7.48$7.555$6.745592,900
Ticker
NASDAQ:UPB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Upstream Bio, Inc. news

Upstream Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 38 in all · newest Nov 10, 2026 · oldest 2024
Decks
6 decks · latest Sep 8, 2026

Where Upstream Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:UPB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:UPBBOATSUnited StatesUSD

Valuation

EV/sales −41.6× against a median of 30.3×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$119.4M USD
P/E
Loss
EV/sales
−41.6×
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
98.3%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.95

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Upstream Bio, Inc. · NASDAQ:UPBUS$87.15M−US$119.4Mn/a−41.6×n/a0.4×n/a0.0×1.95
Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_BUS$88.36MUS$77.74Mn/an/an/a17.0×n/a0.0×n/a
Y-Biologics Inc. · KRX:338840US$88.10MUS$71.36Mn/a30.1×n/a6.8×n/a0.9×n/a
Cumberland Pharmaceuticals Inc. · NASDAQ:CPIXUS$87.57MUS$11.59M1.3×0.5×n/a1.2×273.7%0.1×0.72
Retension Pharmaceuticals, Inc. · NASDAQ:RTSNUS$87.57MUS$78.38Mn/an/an/an/an/an/an/a
Equillium, Inc. · NASDAQ:EQUS$87.26MUS$34.71Mn/an/an/a1.7×n/a0.0×1.31
Senhwa Biosciences Inc · TPEX:6492US$86.77MUS$67.44Mn/a2,117×n/a4.6×n/a0.0×n/a
Bioceltix SA · GPW:BCXUS$86.38MUS$72.43Mn/an/an/a5.6×n/a0.0×n/a
Perspective Therapeutics, Inc. · AMEX:CATXUS$86.05M−US$114.1Mn/a−570×n/a0.3×n/a0.0×1.47
Pharmosa Biopharm Inc. · TPEX:6875US$86.04MUS$62.27Mn/a38.5×n/a2.1×−658.1%0.1×n/a
Formosa Pharmaceuticals, Inc. · TWSE:6838US$85.43MUS$48.52Mn/a30.4×n/a2.0×−361.4%0.0×n/a
Median of the othersUS$87.02MUS$64.86M1.3×30.3×2.1×−361.4%0.0×1.31

Forecasts

5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
24.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.93 · 8 analysts
Revenue, year to Dec 2026
2.59M · 7 analysts

Team and board

Officers

OfficerRole
Rand SutherlandChief Executive Officer
Mike GrayChief Financial Officer and Chief Operating Officer
Allison AmbroseGeneral Counsel
Meggan BuckwellDirector, Corporate Communications and Investor Relations
Amy IannelliVice President, Finance
Ashish KalraVice President, Translational Research
Christopher SilvaVice President, Supply Chain
Edd FlemingExecutive Vice President, Enavate Sciences
Ken AdamsSenior Vice President, Clinical Operations & Medical Writing
Marie SanchiricoVice President, Medical Affairs
Mersedeh MiraliakbariSenior Vice President, Regulatory Affairs and Quality
Parika PetaipimolVice President, Technical Operations
Sumathi SivapalasingamVice President & Head of Clinical Development
Aaron DeykinChief Medical Officer & Head of R&D
Adam HoughtonChief Business Officer
Liam RatcliffeHead of Biotechnology, Access Industries
Marcella K. RuddyChief Medical Officer, Tectonic Therapeutic
Stacy PriceChief Technology Officer

Board

DirectorRole
Ron RenaudChair, Board of Directors
Daniella BeckmanMember, Board of Directors
Edd FlemingExecutive Vice President, Enavate Sciences
Liam RatcliffeHead of Biotechnology, Access Industries

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−5.6%
Q2 2026Aug 11, 2026 · Before open−4.7%
Q1 2026May 13, 2026 · Before open+4.6%
Q4 2025Mar 24, 2026 · Before open0.0%
Q3 2025Nov 5, 2025 · Before open−4.3%
Q2 2025Aug 6, 2025 · Before open+7.9%
Q1 2025May 6, 2025 · Before open−5.4%
Q4 2024Mar 12, 2025+5.8%
Q3 2024Nov 7, 2024 · Before open+1.7%
Q2 2024Aug 28, 2024

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck26 slidesSep 8, 2026
Technical Presentation (September 2026)Technical11 slidesSeptember 2026
Technical Presentation (February 2026)Technical19 slidesFeb 11, 2026
Technical Presentation (September 2025)Technical25 slidesSep 2, 2025
European Respiratory Society (ERS) Congress 2025Conference9 slidesSeptember 2025
Investor Presentation (May 2025)Investor deck30 slidesMay 2025

Open Decks

IPO

Priced at US$17.00 a share on Oct 10, 2024.

Price
US$17.00 a share
Shares offered
15,000,000 shares of common stock
Offering size
US$255 million
Underwriters' option
Up to 2,250,000 more shares
Underwriters
J.P. Morgan, TD Cowen, Piper Sandler, William Blair · In the order on the cover
Shares delivered
On or about Oct 15, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceJun 12, 2024
Filed publiclySep 18, 2024
Amended onceOct 7, 2024
Shares registered with an exchangeOct 8, 2024
Declared effective by the SECOct 10, 2024
Final prospectus, with the priceOct 11, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue2.85M2.37M2.38M1.21M
Cost of revenue188.0K89.0K60.0K7.00K
Gross profit2.85M2.37M2.38M1.21M
Research and development136.8M63.0M31.8M18.7M
Selling, general and administrative26.4M17.2M10.7M6.46M
Operating income-160.4M-77.8M-40.1M-23.9M
Depreciation and amortization188.0K89.0K60.0K7.00K
EBITDA-160.2M-77.7M-40.1M-23.9M
Income before tax-143.4M-62.8M-20.5M-23.9M
Income tax000
Net income-143.4M-62.8M-20.5M-23.9M
Earnings per share, basic-2.66-5.58-12.95-0.66
Earnings per share, diluted-2.66-5.58-12.95

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents101.6M325.9M25.8M17.1M
Short-term investments239.9M144.6M84.0M0
Receivables668.0K613.0K98.0K412.0K
Current assets351.8M479.2M117.0M18.3M
Property, plant and equipment559.0K582.0K159.0K
Goodwill0
Total assets353.8M481.7M117.2M18.5M
Accounts payable2.73M4.04M1.99M712.0K
Current liabilities13.5M10.7M6.51M4.86M
Total debt1.27M1.83M45.0K94.0K
Total liabilities14.0M11.9M9.39M124.6M
Shareholders' equity339.8M469.9M-123.1M-106.2M
Shares outstanding54.2M53.6M2.99M36.3M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-133.3M-59.2M-37.9M-19.0M
Capital spending-165.0K-511.0K-144.0K-82.0K
Free cash flow-133.4M-59.7M-38.1M-19.1M
Cash from investing-93.5M-59.5M-82.8M-82.0K
Cash from financing2.44M418.9M129.6M9.96M
Change in cash-224.3M300.3M8.78M-9.14M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
8-K · Current reportSep 1, 2026Current reportSEC
All 137 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
8-K · Current reportMar 26, 2026Material contractSEC
424B5 · ProspectusMar 26, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 26, 2026Offer documentSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
8-K · Current reportFeb 11, 2026ResultsSEC
8-K · Current reportFeb 11, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
S-3ASR · Registration statementNov 5, 2025Offer documentSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 24, 2025Big-stake noticeSEC
8-K · Current reportSep 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 17, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 12, 2025Offer documentSEC
10-K · Annual reportMar 12, 2025Annual reportSEC
8-K · Current reportMar 12, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 17, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 7, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13D · Big-stake noticeOct 22, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 18, 2024Big-stake noticeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
SC 13D · Big-stake noticeOct 17, 2024Big-stake noticeSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
SEC STAFF LETTEROct 17, 2024Other filingsSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
8-K · Current reportOct 15, 2024Current reportSEC
S-8 · Registration statement for employee plansOct 11, 2024Offer documentSEC
424B4 · ProspectusOct 11, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 11, 2024Other filingsSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringOct 10, 2024Offer documentSEC
3 · Initial statement of ownershipOct 10, 2024Insider tradeSEC
CERT · Exchange's certificate of listingOct 10, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 8, 2024Other filingsSEC
CORRESP · Letter to the SECOct 8, 2024Other filingsSEC
CORRESP · Letter to the SECOct 8, 2024Other filingsSEC
S-1/A · Registration statement, amendedOct 7, 2024Offer documentSEC
CORRESP · Letter to the SECSep 30, 2024Other filingsSEC
CORRESP · Letter to the SECSep 18, 2024Other filingsSEC
S-1 · Registration statementSep 18, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 20, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftAug 9, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedAug 9, 2024Offer documentSEC
UPLOAD · Letter from the SECJul 25, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 18, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJul 18, 2024Offer documentSEC
SEC STAFF LETTERJul 16, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 9, 2024Other filingsSEC
DRS · Draft registration statementJun 12, 2024Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Upstream Bio, Inc.’s releases · as of Nov 6, 2026

Common shares
54,811,391
Fully diluted
54,811,391

Fully diluted

LineSharesAs of
Common shares54,811,391Nov 6, 2026

Share count over time

CountShares
Nov 6, 202654,811,391

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity8.18M14.9%US$43.1MSep 30, 2026
Orbimed Advisors LLC5.69M10.4%US$30MSep 30, 2026
BlackRock3.69M6.7%US$19.4MSep 30, 2026
Vanguard3M5.5%US$15.8MSep 30, 2026
Decheng Capital LLC2.72M5.0%US$14.4MSep 30, 2026
Enavate Sciences Gp, LLC2.46M4.5%US$13MSep 30, 2026
JPMorgan1.46M2.7%US$7.57MSep 30, 2026
D. E. Shaw & Co., Inc.1.4M2.6%US$7.37MSep 30, 2026
Millennium1.17M2.1%US$6.16MSep 30, 2026
Goldman Sachs1.13M2.1%US$5.94MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital973K1.8%US$5.13MSep 30, 2026
Qube Research & Technologies Ltd926K1.7%US$4.88MSep 30, 2026
SEB Asset Management AB878K1.6%US$4.63MSep 30, 2026
Woodline Partners LP831K1.5%US$4.38MSep 30, 2026
Trexquant Investment LP766K1.4%US$4.04MSep 30, 2026
State Street736K1.3%US$3.88MSep 30, 2026
BNP Paribas730K1.3%US$3.85MSep 30, 2026
Y-Intercept (Hong Kong) Ltd643K1.2%US$3.39MSep 30, 2026
Morgan Stanley636K1.2%US$3.35MSep 30, 2026
Parkman Healthcare Partners LLC618K1.1%US$3.26MSep 30, 2026
Voleon Capital Management LP477K0.87%US$2.52MSep 30, 2026
Two Sigma428K0.78%US$2.26MSep 30, 2026
AQR Capital Management LLC416K0.76%US$2.19MSep 30, 2026
Dimensional375K0.68%US$1.97MSep 30, 2026
Point72 Asset Management, L.P.373K0.68%US$1.96MSep 30, 2026
Acadian Asset Management LLC370K0.68%US$1.95MSep 30, 2026
Hrt Financial LP348K0.63%US$1.83MSep 30, 2026
Bank of America346K0.63%US$1.82MSep 30, 2026
Wellington342K0.62%US$1.8MSep 30, 2026
Schwab338K0.62%US$1.78MSep 30, 2026
Propel Bio Management, LLC335K0.61%US$1.77MSep 30, 2026
Sphera Funds Management LTD.326K0.59%US$1.72MSep 30, 2026
Schonfeld Strategic Advisors LLC302K0.55%US$1.59MSep 30, 2026
Samsara Biocapital, LLC300K0.55%US$1.58MSep 30, 2026
Northern Trust289K0.53%US$1.52MSep 30, 2026
Squarepoint Ops LLC276K0.50%US$1.45MSep 30, 2026
XTX Topco Ltd225K0.41%US$1.19MSep 30, 2026
Jump Financial, LLC201K0.37%US$1.06MSep 30, 2026
Barclays198K0.36%US$1.04MSep 30, 2026
Renaissance Technologies195K0.36%US$1.03MSep 30, 2026
Arrowstreet Capital, Limited Partnership190K0.35%US$1MSep 30, 2026
UBS159K0.29%US$839KSep 30, 2026
Jacobs Levy Equity Management, Inc155K0.28%US$817KSep 30, 2026
Walleye Capital LLC155K0.28%US$815KSep 30, 2026
Marshall Wace, LLP136K0.25%US$716KSep 30, 2026
Los Angeles Capital Management LLC133K0.24%US$700KSep 30, 2026
Quantinno Capital Management LP113K0.21%US$594KSep 30, 2026
EntryPoint Capital, LLC106K0.19%US$558KSep 30, 2026
BNY97,1480.18%US$512KSep 30, 2026
Man Group plc88,7820.16%US$468KSep 30, 2026

This page holds 50 of 131 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.44M2.6%US$9.99MJun 30, 2026
Fidelity Small Cap Growth Fund1.37M2.5%US$8.65MJul 31, 2026
Fidelity Stock Selector Small Cap Fund1.32M2.4%US$8.34MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund966K1.8%US$6.09MJul 31, 2026
iShares Russell 2000 ETF921K1.7%US$6.37MJun 30, 2026
Select Health Care Portfolio800K1.5%US$6.69MMay 31, 2026
Fidelity Small Cap Growth K6 Fund694K1.3%US$4.38MJul 31, 2026
Fidelity Advisor Biotechnology Fund691K1.3%US$4.36MJul 31, 2026
Fidelity Advisor Health Care Fund400K0.73%US$2.52MJul 31, 2026
Vanguard Extended Market Index Fund387K0.71%US$2.68MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Small Cap Index Fund385K0.70%US$2.43MJul 31, 2026
BlackRock Health Sciences Opportunities Portfolio342K0.62%US$2.86MMay 29, 2026
iShares Russell 2000 Value ETF338K0.62%US$2.34MJun 30, 2026
iShares Biotechnology ETF256K0.47%US$1.77MJun 30, 2026
Select Biotechnology Portfolio235K0.43%US$1.96MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund235K0.43%US$1.62MJun 30, 2026
Fidelity Extended Market Index Fund178K0.32%US$1.49MMay 31, 2026
Vanguard Market Neutral Fund169K0.31%US$1.17MJun 30, 2026
Vanguard Russell 2000 Index Fund168K0.31%US$1.41MMay 31, 2026
Schwab U.S. Small-Cap ETF162K0.29%US$1.35MMay 31, 2026
Dimensional U.S. Small Cap ETF151K0.27%US$950KJul 31, 2026
VIP Health Care Portfolio145K0.26%US$1MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund137K0.25%US$1.14MMay 31, 2026
Fidelity Series Small Cap Core Fund132K0.24%US$834KJul 31, 2026
Fidelity Small Cap Stock Fund132K0.24%US$831KJul 31, 2026
Fidelity Fundamental Small-Mid Cap ETF93,7120.17%US$591KJul 31, 2026
Schwab Small-Cap Index Fund84,9390.15%US$536KJul 31, 2026
Fidelity Small Cap Discovery Fund75,3000.14%US$475KJul 31, 2026
U.S. Micro Cap Portfolio73,5500.13%US$464KJul 31, 2026
Vanguard Health Care Index Fund72,4720.13%US$606KMay 31, 2026
Fidelity Series Small Cap Discovery Fund69,3060.13%US$437KJul 31, 2026
Fidelity Total Market Index Fund64,3880.12%US$538KMay 31, 2026
Avantis U.S. Small Cap Equity ETF62,6060.11%US$523KMay 31, 2026
Simplify Propel Opportunities ETF62,1130.11%US$430KJun 30, 2026
Fidelity Enhanced Small Cap Core ETF61,6820.11%US$427KJun 30, 2026
Master Small Cap Index Series55,9000.10%US$387KJun 30, 2026
ALPS Medical Breakthroughs ETF55,6990.10%US$466KMay 31, 2026
Fidelity Series Total Market Index Fund51,7940.09%US$433KMay 31, 2026
Virtus Biotech Clinical Trials Etf50,9520.09%US$322KJul 31, 2026
JPMorgan Small Cap Value Fund49,6780.09%US$344KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF49,6390.09%US$344KJun 30, 2026
Fidelity Small Cap Value Index Fund49,3420.09%US$341KJun 30, 2026
Nuveen Small Cap Blend Index Fund46,9240.09%US$296KJul 31, 2026
U.S. Small Cap Portfolio39,6240.07%US$250KJul 31, 2026
EQ/2000 Managed Volatility Portfolio36,0470.07%US$249KJun 30, 2026
Fidelity Nasdaq Composite Index Fund35,3470.06%US$296KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF33,6980.06%US$213KJul 31, 2026
Allspring Disciplined Small Cap Fund28,9130.05%US$200KJun 30, 2026
Nuveen Equity Index Fund28,7180.05%US$181KJul 31, 2026
Vanguard Balanced Index Fund26,4070.05%US$183KJun 30, 2026

This page holds 50 of 147 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ambrose Allison
Officer: General Counsel
Sale485USD 5.49US$2,663Sep 16, 2026
Gray Michael
Officer: CFO and COO
Sale853USD 5.49US$4,683Sep 16, 2026
Houghton Adam
Officer: Chief Business Officer
Sale700USD 5.49US$3,843Sep 16, 2026
Sutherland Everett Rand
Director, Officer: Chief Executive Officer
Sale2,095USD 5.49US$11,502Sep 16, 2026
Deykin Aaron
Officer: Chief Medical Officer
Sale895USD 5.49US$4,914Sep 16, 2026
Ambrose Allison
Officer: General Counsel
Sale477USD 6.10US$2,910Jun 16, 2026
Deykin Aaron
Officer: Chief Medical Officer
Sale895USD 6.10US$5,460Jun 16, 2026
Houghton Adam
Officer: Chief Business Officer
Sale700USD 6.10US$4,270Jun 16, 2026
Sutherland Everett Rand
Director, Officer: Chief Executive Officer
Sale2,095USD 6.10US$12,780Jun 16, 2026
Gray Michael
Officer: CFO and COO
Sale853USD 6.10US$5,203Jun 16, 2026

Big stakes

StakeStakeSharesDateFiling
Norges Bank7.73%4.21MJun 30, 2026Schedule 13G
FMR LLC6.90%3.79MOct 30, 2026Schedule 13G
BlackRock, Inc.5.20%2.81MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Daniella Beckman
Other companies: Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past)
Member, Board of Directors · Since at least Oct 10, 2024
Everett Rand Sutherland
Other companies: Krystal Biotech, Inc. (Director · Since at least Jan 18, 2022); Allakos Inc (Director · Jul 31, 2023 – Aug 1, 2023 · Past); Translate Bio Inc (President · Mar 22, 2021 – Sep 14, 2021 · Past)
Chief Executive Officer, Director · Since at least Oct 10, 2024
Michael Gray
Other companies: POINT Biopharma Global Inc (Director · Jul 7, 2020 – Jul 7, 2020 · Past); Enliven Therapeutics, Inc. (CFO & COO · Mar 11, 2020 – Feb 22, 2023 · Past); X4 Pharmaceuticals, Inc. (President, CEO and CFO, Director · Nov 15, 2017 – Nov 27, 2018 · Past)
CFO and COO · Since at least Oct 10, 2024
Harold Edward Fleming
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); CRISPR Therapeutics AG (Director · Since at least Jun 10, 2021)
Director · Since at least Oct 10, 2024
Marcella Kuhlman Ruddy
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Tectonic Therapeutic, Inc. (Chief Medical Officer · Since at least Jun 20, 2024)
Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024
Edd Fleming
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Nov 5, 2026)
Executive Vice President, Enavate Sciences · Since at least Nov 5, 2026
Rand Sutherland
Other companies: Krystal Biotech, Inc. (Board Member · Since at least Nov 5, 2026)
Chief Executive Officer · Since at least Aug 11, 2026
Aaron DeykinChief Medical Officer & Head of R&D · Since at least Jun 16, 2026
Adam HoughtonChief Business Officer · Since at least Jun 16, 2026
Allison AmbroseGeneral Counsel · Since at least Dec 16, 2024
All 23 people
PersonSeat
Amy IannelliVice President, Finance · Since at least Nov 5, 2026
Ashish KalraVice President, Translational Research · Since at least Jun 5, 2025
Christopher SilvaVice President, Supply Chain · Since at least Nov 5, 2026
Ken AdamsSenior Vice President, Clinical Operations & Medical Writing · Since at least Nov 4, 2026
Liam RatcliffeHead of Biotechnology, Access Industries · Since at least Nov 5, 2026
Marie SanchiricoVice President, Medical Affairs · Since at least Nov 5, 2026
Meggan BuckwellDirector, Corporate Communications and Investor Relations · Since at least Mar 1, 2026
Mersedeh MiraliakbariSenior Vice President, Regulatory Affairs and Quality · Since at least Nov 5, 2026
Mike GrayChief Financial Officer and Chief Operating Officer · Since at least Sep 17, 2026
Parika PetaipimolVice President, Technical Operations · Since at least Nov 5, 2026
Ron RenaudChair, Board of Directors · Since at least Nov 4, 2026
Stacy PriceChief Technology Officer · Since at least May 20, 2025
Sumathi SivapalasingamVice President & Head of Clinical Development · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Upstream Bio, Inc.